Your browser doesn't support javascript.
loading
The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.
Hydes, Theresa J; Kennedy, Oliver J; Buchanan, Ryan; Cuthbertson, Daniel J; Parkes, Julie; Fraser, Simon D S; Roderick, Paul.
Afiliação
  • Hydes TJ; Department of Cardiovascular and Metabolic Medicine, 3Rd Floor Clinical Sciences Centre, Institute of Life Course and Medical Sciences, Liverpool University Hospitals NHS Foundation Trust, University of Liverpool, Longmoor Lane, Liverpool, L9 7AL, UK. theresa.hydes@liverpool.ac.uk.
  • Kennedy OJ; University Hospital Aintree, Liverpool University Hospital NHS Foundation Trust, Liverpool, L9 7AL, UK. theresa.hydes@liverpool.ac.uk.
  • Buchanan R; School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, SO17 1BJ, UK.
  • Cuthbertson DJ; School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, SO17 1BJ, UK.
  • Parkes J; Department of Hepatology, University Hospitals Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK.
  • Fraser SDS; NIHR Southampton Biomedical Research Centre, Southampton General Hospital, Southampton, SO16 6YD, UK.
  • Roderick P; Department of Cardiovascular and Metabolic Medicine, 3Rd Floor Clinical Sciences Centre, Institute of Life Course and Medical Sciences, Liverpool University Hospitals NHS Foundation Trust, University of Liverpool, Longmoor Lane, Liverpool, L9 7AL, UK.
BMC Med ; 21(1): 185, 2023 05 18.
Article em En | MEDLINE | ID: mdl-37198624
ABSTRACT

BACKGROUND:

Chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) frequently co-exist. We assess the impact of having NAFLD on adverse clinical outcomes and all-cause mortality for people with CKD.

METHODS:

A total of 18,073 UK Biobank participants identified to have CKD (eGFR < 60 ml/min/1.73 m2 or albuminuria > 3 mg/mmol) were prospectively followed up by electronic linkage to hospital and death records. Cox-regression estimated the hazard ratios (HR) associated with having NAFLD (elevated hepatic steatosis index or ICD-code) and NAFLD fibrosis (elevated fibrosis-4 (FIB-4) score or NAFLD fibrosis score (NFS)) on cardiovascular events (CVE), progression to end-stage renal disease (ESRD) and all-cause mortality.

RESULTS:

56.2% of individuals with CKD had NAFLD at baseline, and 3.0% and 7.7% had NAFLD fibrosis according to a FIB-4 > 2.67 and NFS ≥ 0.676, respectively. The median follow-up was 13 years. In univariate analysis, NAFLD was associated with an increased risk of CVE (HR 1.49 [1.38-1.60]), all-cause mortality (HR 1.22 [1.14-1.31]) and ESRD (HR 1.26 [1.02-1.54]). Following multivariable adjustment, NAFLD remained an independent risk factor for CVE overall (HR 1.20 [1.11-1.30], p < 0.0001), but not ACM or ESRD. In univariate analysis, elevated NFS and FIB-4 scores were associated with increased risk of CVE (HR 2.42 [2.09-2.80] and 1.64 [1.30-2.08]) and all-cause mortality (HR 2.82 [2.48-3.21] and 1.82 [1.47-2.24]); the NFS score was also associated with ESRD (HR 5.15 [3.52-7.52]). Following full adjustment, the NFS remained associated with an increased incidence of CVE (HR 1.19 [1.01-1.40]) and all-cause mortality (HR 1.31 [1.13-1.52]).

CONCLUSIONS:

In people with CKD, NAFLD is associated with an increased risk of CVE, and the NAFLD fibrosis score is associated with an elevated risk of CVE and worse survival.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Hepatopatia Gordurosa não Alcoólica / Falência Renal Crônica Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Hepatopatia Gordurosa não Alcoólica / Falência Renal Crônica Idioma: En Ano de publicação: 2023 Tipo de documento: Article